What is Roivant Sciences Ltd (ROIV)?
Roivant Sciences Ltd is a biopharmaceutical company focused on the development and commercialization of innovative therapies. The company operates by identifying and acquiring promising drug candidates, often through subsidiary ventures known as 'Vants,' which specialize in various therapeutic areas. Roivant's business model emphasizes efficient drug development processes and strategic partnerships to advance treatments for diseases with unmet medical needs. The company integrates technology and data analytics to optimize clinical development and regulatory strategies. Its portfolio spans multiple therapeutic domains, including neurology, oncology, and rare diseases. Roivant Sciences Ltd aims to streamline drug development timelines and enhance the probability of successful commercialization. The company is headquartered in the United States and engages in collaborations with academic institutions, pharmaceutical companies, and healthcare organizations to support its research and development activities. Through its diversified approach, Roivant contributes to the broader biopharmaceutical industry by advancing novel therapies toward regulatory approval and patient access.
Roivant Sciences Ltd Stock Price Today: Live Overview
The price today is shaped by trading activity, as High Tide Inc is trading at $26.93. The daily price has ranged from $26.53 to $27.68, with a daily percentage change of -3.6944%.
FAQ: Roivant Sciences Ltd (ROIV)
What is the current price of ROIV stock?
The stock price is currently $26.93.
Does ROIV pay dividends?
Roivant Sciences Ltd does not pay dividends.
Does ROIV have a formal corporate presence or regional headquarters in the UAE?
Roivant Sciences Ltd operates via partners in the UAE without an official regional office or subsidiary.
What is ROIV best known for?
The company is most famous for its biopharmaceutical research and development.
What assets are typically shown together with ROIV?
Commonly shown alongside ROIV: KT Corp SP, Hub Group Inc, New World Dev
Latest shares articles



